The 1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025 is scheduled to take place as a hybrid meeting from 21-22 May 2025 in New Orleans, LA, United States. 

The Abstract Submission Portal for LAAI 2025 is now open! Click here for more information. Abstract Submission Deadline is Friday, 28 February 2025 at 11:59 PM EST

----

The International Workshop On Long Acting Anti-Infectives (LAAI) is a crucial platform for advancing the development, implementation, and scale-up of long-acting and extended-release (LA/ER) anti-infective therapies. This 1st edition of the workshop will explore the transformative potential of LA/ER drug delivery in infectious disease management, with a focus on recent breakthroughs in HIV prevention and treatment.

Attendees will discuss the clinical application of these therapies in populations with historically low adherence, including pediatric patients, pregnant and breastfeeding women, and individuals experiencing homelessness.

By sharing knowledge on trial design, safety, efficacy, and implementation strategies, this 2-day hybrid workshop will contribute to the global effort to improve health outcomes, extending the benefits of these therapies beyond HIV to other infectious diseases like tuberculosis, malaria, and viral hepatitis.

We are excited to announce that the 1st LAAI 2025 will take place at the Renaissance New Orleans Pere Marquette French Quarter Area Hotel, located in New Orleans, United States.

Who Should Attend?
- Clinicians;
- Researchers;
- Clinical pharmacologists;
- Pharmacists;
- Industry representatives;
- Regulatory scientists;
- Government representatives;
- Post-graduate students;
- Other professionals involved in the development of novel anti-infective therapy

Meeting Objectives
This meeting aims to:
- Foster interdisciplinary collaboration to accelerate the development and evaluation of long-acting anti-infective interventions targeting a spectrum of infectious diseases;
- Discuss the efficacy, safety, and accessibility of novel agents across diverse populations;
- Outline the patterns of anti-infective drug resistance and devise strategies to mitigate the impact of drug resistance on treatment outcomes and public health;
- Develop actionable recommendations aimed at enhancing access, adherence, and outcomes for LA anti-infective treatments.

For more information, please visit the official event page.